Articles On Starpharma Holdings (ASX:SPL)

A quick wrap of the ASX’s key winners and losers on Tuesday, August 25. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made market-moving announcements during the day. Today 782 stocks rose, 682 declined and...

The Starpharma Holdings Limited (ASX: SPL) share price bolted more than 14% in early trade today. The positive price action follows an announcement from the company regarding a nasal spray for COVID-19. Details on Starpharma’s nasal spray...

Starpharma (ASX:SPL) has updated on progress in the development, regulatory and manufacturing activities associated with a nasal spray for protection against COVID-19 based on the company’s proprietary antiviral dendrimer, SPL7013....

Australian company Starpharma (ASX:SPL) has signed a new research partnership with Chinese Pharmaceutical company Tianjin Chase Sun Pharmaceutical to develop several DEP nanoparticle formulations for an anti-infective drug.

The Starpharma Holdings Limited (ASX: SPL) share price is bucking the market downtrend today after the biotech announced a new partnership deal. The news isn’t quite as exciting as Mesoblast limited’s (ASX: MSB) FDA announcement, but share...

The S&P/ASX 200 Index (ASX: XJO) has started the week on a disappointing note. In late morning trade the benchmark index is down 0.9% to 6,070.1 points. Four shares that have not let that hold them back are listed below. Here’s why the...

With its stock plumbing all time lows, G Medical (ASX:GMV) is making good on a promise first made in 2018 to list on the NASDAQ tech exchange in New York. The medical device company will delist from the ASX in order to list in the US, an ev...

Starpharma (ASX:SPL) has announced the opening of the MD Anderson Cancer Center as another site for the phase one trial of AZD0466 - AstraZeneca’s first DEP product.

After a strong start to the day, the S&P/ASX 200 Index (ASX: XJO) is currently fighting hard to stay in positive territory. In late morning trade the benchmark index is up slightly to 5,944.4 points. Four shares that are climbing more...

16 Jun 2020 - Starpharma (ASX:SPL) today announced that VivaGel BV has been launched in Central and Eastern European region.

COVID-19 vaccines are driving markets but treatments are where most people believe a solution to the pandemic lies. However, use of the two most famous treatments to date — Gilead Sciences’ HIV drug remdesivir and US President Donald Trump’...

The S&P/ASX 200 Index (ASX: XJO) is out of form and on course to record a disappointing decline. In late morning trade the benchmark index is down 1.45% to 5,387.6 points. Four shares that have not let that hold them back today are lis...

The S&P/ASX 200 Index (ASX: XJO) may be sinking lower today, but that hasn’t stopped the Starpharma Holdings Limited (ASX: SPL) share price from rocketing higher. In morning trade the dendrimer products developer’s shares zoomed a mass...

04 Mar 2020 - Starpharma (ASX:SPL) today announced that following the successful launch of the VivaGel antiviral condom by Okamoto Industries in Japan, they are now seeking to expa…

Neuren Pharmaceuticals (ASX:NEU) has been granted Rare Pediatric Disease (RPD) designation for its Rett syndrome treatment, a serious and rare neurological disorder mainly affecting little girls. The US Food and Drug Administration (FDA) gr...

The Starpharma Holdings Limited (ASX: SPL) share price is pushing higher this morning following the release of an update on its VivaGel product. At the time of writing its shares have avoided the market selloff and are up 0.5% to $1.01. Wh...

The Starpharma Holdings Limited (ASX: SPL) share price has dropped lower with the market on Monday following the release of its half year results. At the time of writing the dendrimer products developer’s shares are down 6.5% to $1.14. How...

Sleep apnoea — or sleep suffocation as some have taken to calling it — is big business on the ASX, spanning billion-dollar ResMed (ASX:RMD) to a group of small caps. Oventus (ASX:OVN), one of those small caps, is the latest this month to ad...

AstraZeneca has paid a $4.5 million milestone payment to Australian company Starpharma (ASX:SPL) following the successful dosing of the first patient in the phase 1 clinical trial of AZD0466.

The Starpharma Holdings Limited (ASX: SPL) share price is pushing higher on Thursday after the release of a positive update. In morning trade the dendrimer products developer’s shares are up 3% to $1.17. What did Starpharma announce? Inves...

Starpharma Holdings (SPL) has received a milestone $4.5 million payment from biopharmaceutical giant AstraZeneca The grant follows the first successful human dosing in AstraZeneca’s cancer treatment trial, which uses Starpharma’s drug deli...

The Starpharma Holdings Limited (ASX: SPL) share price will be on watch today following an update on its phase 1 trial of AZD0466. At the time of writing, the Starpharma share price is up by 2.16%. What does Starpharma do? Starpharma is an...

Two more coronavirus infections were released to the ASX in the last 24 hours, but while one was bad, it turns out the other wasn’t part of the epidemic at all. Uscom (ASX:UCM) says sales of its haemodynamic monitoring device in China, whic...

Australian Biotech Starpharma (SPL) has released its quarterly cash flow report for the December 2019 quarter Cash balance for the end of the quarter was just under $36 million The company also had net operating cash outflows of $500,000...

You don’t need a PhD to run a biotech, but sometimes it helps, as these companies deal in one of the most complicated mysteries still to be solved today: the human body. Biotech CEOs and chairs tend to be the cross-over scientists. However,...

In afternoon trade the S&P/ASX 200 index is on course to start the week on a disappointing note. At the time of writing the benchmark index is down 0.45% to 6,790.8 points. Four shares that have not let that hold them back today are li...

AstraZeneca has begun the phase 1 clinical trial for a cancer treatment drug Roughly $4.29 million will be paid to StarPharma (SPL) as a result of the trial The drug comes under a multi-product license for AstraZeneca to develop treatments...

The Starpharma Holdings Limited (ASX: SPL) share price is pushing higher on Monday. In morning trade the dendrimer products developer’s shares are up 2% to $1.22 following an announcement. What did Starpharma announce? This morning Starpha...

Whether a day trader or a long-term investor, we often examine research released by industry experts, brokers and analysts with a view to uncovering the next big thing. The more complex the sector, the more we are likely to rely on informat...

Starpharma Holdings Limited (ASX: SPL) has received a $4.9 million R&D tax incentive refund related to the cost of research and development during FY19. As per the company, the refund will strengthen the company’s cash position. For the...

Pharmaxis (ASX:PXS) has some big news from its German partner, but won’t yet say whether it’s good or bad. The company has been waiting on pharmaceutical major Boehringer Ingelheim to decide whether it wants to go ahead and further develop...

The primary research tool in advancing medical knowledge and patient care are clinical trials conducted when doctors do not know whether a new approach works well for patients and is safe, and which treatments or strategies work best for ce...

Starpharma Holdings Limited (ASX: SPL) has announced the completion of the phase 1 component of its phase 1 / 2 trial for DEP® cabazitaxel.  The trial was able to meet its objective of assessing safety, tolerability and preliminary efficacy...

In afternoon trade the S&P/ASX 200 index is on course to follow the lead of U.S. markets and drop lower. At the time of writing the benchmark index is down 0.2% to 6,716.5 points. Four shares that have not let that hold them back are l...

10 Dec 2019 - Starpharma's (ASX:SPL) prostate cancer drug DEP cabazitaxel has successfully completed its phase one trials.

Starpharma’s (ASX:SPL) cancer drug has passed its first test, proving to be safe and delivering a recommended dose. The company is taking a version of cancer drug Jevtana through phase 1 and 2 clinical trials, as a treatment for cancers inc...

Shares in Starpharma (ASX: SPL) couldn't get up by market close today despite a landmark approval for the biotech's VivaGel condoms to be marketed in Europe. The Melbourne-based company describes the condom as a world-first product and th...

Starpharma (ASX:SPL) has announced it has been granted marketing approval for its VivaGel condom in Europe. 

21 Nov 2019 - Starpharma (ASX:SPL) has been granted marketing approval for the VivaGel® condom in Europe.

The Starpharma Holdings Limited (ASX: SPL) share price will be on watch on Thursday following an after-market announcement. What did Starpharma announce? This afternoon Starpharma announced that it has been granted marketing approval for...

Short & Caught is Stockhead’s fortnightly recap of which ASX small cap stocks are heavily shorted. Stocks that are shorted have investors betting that they fall. Shorting works by selling stocks you do not actually own in the hope of bu...

The Starpharma Holdings Limited (ASX: SPL) share price is pushing higher on Wednesday. In morning trade the dendrimer products developer’s shares are up 3% to $1.36. Why is the Starpharma share price pushing higher? Investors have been buy...

Health care sector in Australia is growing tremendously and players are investing a considerable amount in their research and development for providing new treatment for rare diseases and finding therapies for unmet medical needs. Clinical...

The Starpharma Ltd (ASX: SPL) share price has been fluctuating in trade today after its latest development update. Starpharma shares climbed as high as $1.19 on the announcement, but have since dipped back down to $1.15 at the time of writ...

31 Oct 2019 - Starpharma (ASX:SPL) says their next internal development candidate, DEP® gemcitabine significantly enhanced anti-tumour activity compared with Gemzar® both alone and…

The Starpharma Holdings Limited (ASX: SPL) share price was a strong performer on Wednesday. The dendrimer products developer’s shares finished the day 5% higher at $1.16. Why did the Starpharma share price race higher today? The catalyst f...

Pharmacy businesses are increasingly becoming a focal point for investments by businesses and market players, given the huge market opportunity that lies ahead. As per the US National Institute of Health, the development of a new medicine i...

The S&P/ASX 200 index is on course to finish the week on a positive note. In afternoon trade the benchmark index is up almost 0.5% to 6,708.8 points. Four shares that have failed to follow the market higher today are listed below. Here...

It certainly has been a positive day of trade for the Stavely Minerals Ltd (ASX: SVY) share price. In afternoon trade the copper and gold-focused mineral exploration company’s shares are up an incredible 287% to 93 cents. Why is the Stavel...

In afternoon trade the S&P/ASX 200 index is on course to record another decline. At the time of writing the benchmark index is down 0.35% to 6,687.3 points. Four shares that have not let that hold them back are listed below. Here’s why...